SCHEMBL22521022

SCHEMBL22521022

Cc1ccc(-c2cnn3c(S)cc(C)nc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.55
▸ RAB9A P51151 12/20 0.55
▸ NPC1 O15118 11/20 0.55
▸ SMN1; SMN2 Q16637 5/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ KDM4E B2RXH2 8/20 0.55
▸ MEN1 O00255 7/20 0.55
▸ KMT2A Q03164 7/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ HPGD P15428 4/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ HSD17B10 Q99714 4/20 0.54
▸ MAPK1 P28482 3/20 0.54
▸ TP53 P04637 2/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19668734 0.88 RAB9A (0.71) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22520838 0.88 RAB9A (0.71) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22520813 0.86 MAPT (0.67) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22520826 0.82 MAPT (0.55) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22521012 0.79 CHEK1 (0.46) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22521038 0.77 MEN1 (0.52) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22520816 0.77 MAPT (0.44) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL10407273 0.75 KDM4E (0.41) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL22520952 0.73 MEN1 (0.61) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1
SCHEMBL11744578 0.73 MAPT (0.48) MAPTRAB9ANPC1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163489-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME NYSNOBIO IRELAND DAC (IE) 2021-06-03 — — US disclosed
US-20200317674-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME An2H Discovery Limited (IE) 2020-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317674-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME PINK1, ADRM1, LRRK2 MAPT 2001/4885RAB9A 1673/4885NPC1 2006/4885
US-20210163489-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME PINK1, ADRM1, LRRK2 MAPT 2001/4885RAB9A 1673/4885NPC1 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback